Signaling antibodies in cancer therapy

Current Opinion in Immunology

Volumn 11, Issue 5, 1999, Pages 541-547

  Cragg, Mark S ^a   French, Ruth R ^a   Glennie, Martin J ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CANCER ANTIBODY; CD20 ANTIGEN; FLUDARABINE; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; ONCOPROTEIN; RITUXIMAB; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CROSS LINKING; DRUG MECHANISM; DRUG SENSITIZATION; EFFECTOR CELL; GENETIC ENGINEERING; HUMAN; MACROPHAGE; NATURAL KILLER CELL; ONCOGENE NEU; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 0032826180     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)00010-2     Document Type: Review

References (57)

1. Scott MS, Welt S Antibody-based immunological therapies. Curr Opin Immunol. 9:1997;717-722.
2. Multani PS, Grossbard ML Monoclonal antibody-based therapies for hematologic malignancies. J Clin Oncol. 16:1998;3691-3710.
3. Buske C, Feuring-Buske M, Unterhalt M, Hiddemann W Monoclonal antibody therapy for non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategy. Eur J Cancer. 35:1999;549-557.
4. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles T-M, Dallaire BKet al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90:1997;2188-2195.
5. 2at weekly intervals. 48% of patients responded (6% completely) with a median response duration of 11.8 months. This is comparable to results with single-agent chemotherapy. Toxicity was mild (grade 1 and 2) and seen mainly during the first infusion. Only one patient developed a response involving anti-chimeric antibody.
6. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JAet al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 92:1998;1927-1932. Fifty-four patients with aggressive B cell tumors received eight weekly infusions of Rituximab (in two dose regimes). Five complete and twelve partial remissions were achieved (a 31% response in total) with normal levels of infusion-related toxicity. Thus anti-CD20, although not quite as active against more aggressive tumors, is nonetheless effective and deserves further investigation.
7. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annals Oncol. 9:1998;995-1001. High levels of serum Rituximab (with a median of 20.3 μg/ml at three months) are achieved following treatment. A positive correlation is reported in 166 patients between the median antibody concentration and clinical response. These results suggest that certain patients may benefit from increased dosing.
8. Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW IDEC C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorder: evaluation of response on 48 patients. Eur J Haem. 62:1999;76-82. In this study, 21% partial remission was achieved overall with no complete remissions. The results suggest that the CD20 density and the type of B cell neoplasia are critical factors in the success of anti-CD20 mAb treatment. Follicular centre cell lymphoma is the most responsive.
9. Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 17:1999;791-795. Five patients with high numbers of circulating neoplastic B cells were given Rituximab. The rapid clearance of these cells was associated with severe infusion-related reactions, which required hospitalisation. Four of these patients were re-treated without complications.
10. Davis TA, Czerwinski DK, Levy R Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 5:1999;611-615.
11. Goldenberg MM Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 21:1999;309-318. An up-to-date review of the anti-Her-2 mAb in the treatment of breast cancer.
12. Osterborg A, Dyer MJS, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol. 15:1997;1567-1574.
13. Pawson R, Dyer MJS, Barge R, Matutes E, Thornton PD, Emmett E, Kluin-Nelemans JC, Fibbe WE, Willemze R, Catovsky D Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 15:1997;2667-2672.
14. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche Het al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 16:1998;1788-1794. This reports a seven-year follow-up of a large multicenter trial using a mAb directed against the 17-1A antigen. Antibody administered after surgery reduced overall mortality by 32% and reduced the recurrence rate by 23%.
15. Herlyn D, Koprowski H IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci USA. 79:1982;4761-4765.
16. Seto M, Takahashi T, Nakamura S, Matsudaira Y, Nishizuka Y In vivo antitumor effects of monoclonal antibodies with different immunoglobulin classes. Cancer Res. 43:1983;4768-4773.
17. Denkers EY, Badger CC, Ledbetter JA, Bernstein ID Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol. 135:1985;2183-2186.
18. Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol. 136:1986;1123-1130.
19. Hale G, Clark M, Waldmann H Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol. 134:1985;3056-3061.
20. Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H Effects of Campath-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 73:1989;1431-1439.
21. Shaw DR, Khazaeli MB, Lobuglio AF Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses. J Natl Cancer Inst. 80:1988;1553-1559.
22. Vaughan TJ, Osbourn JK, Tempest PR Human antibodies by design. Nat Biotechnol. 16:1998;535-539.
23. Vitetta ES, Uhr JW Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. Cancer Res. 54:1994;5301-5309.
24. Vuist WMJ, Levy R, Maloney DG Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumour expression of high levels of Bcl-2 protein. Blood. 83:1994;899-906.
25. Davis TA, Maloney DG, Czerwinski DK, Liles T-M, Levy R Anti idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood. 92:1998;1184-1190. This is the first demonstration that NHL patients in long-term remission after treatment with anti-Id mAbs still harbour dormant tumor. Five patients who had been in remission for 3-8 years were evaluated by a range of techniques, including sensitive PCR, and shown to have tumor in blood and/or bone marrow expressing the tumor-specific immunoglobulin CDR3 DNA sequences.
26. Tutt AL, French RR, Illidge TM, Honeychurch J, McBride HM, Penfold CA, Fearon DT, Parkhouse RME, Klaus GGB, Glennie MJ Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J Immunol. 161:1997;3176-3185.
27. Marches R, Scheuermann RH, Uhr JW Cancer dormancy: role of cyclin-dependent kinase inhibitors in induction of cell cycle arrest mediated via membrane IgM. Cancer Res. 58:1998;691-697.
28. Healy JI, Goodnow CC Positive versus negative signaling by lymphocyte antigen receptors. Annu Rev Immunol. 16:1998;645-670. An up-to-date and comprehensive review on how signaling through the antigen-receptors on lymphocytes can result in opposing fates - life or death.
29. 1. J Immunol. 138:1987;628-634.
30. + T cells to induce dormancy in these mice.
31. Vitetta ES, Tucker TF, Racila E, Huang YW, Marches R, Lane N, Scheuermann RH, Street NE, Watanabe T, Uhr JW Tumor dormancy and signaling (V): regrowth of the BCL1 tumor after dormancy is established. Blood. 89:1997;4425-4436.
32. Deans JP, Schieven GL, Shu GL, Valentine MA, Gilliland LA, Aruffo A, Clark EA, Ledbetter JA Association of tyrosine and serine kinases with the B cell surface antigen CD20: induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma I and phospholipase C-gamma II. J Immunol. 151:1993;4494-4504.
33. Poppoff IJ, Savage JA, Blake J, Johnson P, Deans JP The association between CD20 and Src-family tyrosine kinases requires an additional factor. Molec Immunol. 35:1998;207-214.
34. Leveille C, Aldaccak R, Mourad W CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur J Immunol. 29:1999;65-74.
35. Maloney DJ, Smith B, Applebaum FR The antitumor effect of monoclonal anti-CD20 therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood. 88(suppl 1):1996;2535.
36. Mathas S, Bommert K, Dorken B, Mapara MY Anti-CD20 antibody mediated apoptosis is dependent on caspase 3 activation. Blood. 92(suppl 1):1998;1671.
37. Shan D, Ledbetter JA, Press OW Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 91:1998;1644-1652. Evidence that anti-CD20 mAbs induce growth inhibition and apoptosis in a number of B cell lines and that this function may confer the potent therapeutic effects seen in the clinic. These effects were greatly enhanced by further crosslinking of the mAb by polyclonal anti-mouse antibodies or FcR-bearing cells.
38. 131I labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res. 52:1992;6476-6481.
39. Hooijberg E, Sein JJ, van den Berk PCM, Hart AAM, van der Valk MA, Kast WM, Melief CJM, Hekman A Eradication of large human tumours in nude-mice with unconjugated CD20 mAbs and IL-2. Cancer Res. 55:1995;2627-2634.
40. Mendelsohn J Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 3:1997;2703-2707.
41. Hynes NE, Stern DF The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1198:1994;165-184.
42. Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A, Shepard HM Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor-cell growth. Growth Regulat. 1:1991;72-82.
43. O'Hagan RC, Hassell JA The PEA3 Ets transcription factor is a downstream target of the HER2/neu receptor tyrosine kinase. Oncogene. 16:1998;301-310.
44. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ Monoclonal antibody to HER2-neu receptor modulates repair of radiation induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 59:1999;1347-1355. This is a key study, demonstrating the potent synergistic effects of combining irradiation with anti-Her-2 mAb therapy. This work demonstrated that anti- Her-2 mAbs influence DNA repair and p21WAF1 levels after irradiation, illustrating a possible mechanism whereby potent therapeutic effects are induced.
45. Katsumata M, Okudaira T, Samanta A, Clark DP, Drebin JA, Jolicoeur P, Greene MI Prevention of breast tumor development in-vivo by down-regulation of the p185 (neu) receptor. Nat Med. 1:1995;644-648.
46. Zhang L, Lau Y-K, Xia W, Hortobagyi GN, Hung M-C Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res. 5:1999;343-353. The tyrosine kinase inhibitor emodin mimics the effects of mAbs to the Her-2 molecule on breast cells overexpressing this receptor and demonstrates a similar synergistic therapeutic response in combination with paclitaxel.
47. Lui Y, Martindale J, Gorospe M, Holbrook N Regulation of 21/WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res. 56:1996;31-35.
48. Demiden T, Lam S, Alas S, Hariharan K, Hanna N, Bonavida B Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Can Biother Radiopharm. 12:1997;177-186.
49. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, Lobuglio AF, Klippenstein D, Dallaire B, Varns C Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 17:1999;268-276.
50. TM) enhances the antitumor activity of paclitaxel and doxirubicin against Her2/neu overexpressing breast cancer xenografts. Cancer Res. 58:1998;2825-2831. A clear demonstration that the humanized anti-Her-2 antibody can potentiate the effects of two standard chemotherapeutic agents. This study illustrates the need to explore the signaling pathways involved, as combinations with paclitaxel were far more effective than those with doxirubicin.
51. Illidge TM, Cragg MS, McBride H, French RR, Glennie MJ Radioimmunotherapy of B-cell lymphoma: the importance of antibody-specificity in determining successful treatment of established disease. Blood. 94:1999;233-243. This paper illustrates that the specificity of the mAb is vital in the delivery of radiation through radioimmunotherapy. Signaling mAbs (anti-Id) yield far more impressive therapeutic effects in the treatment of mice late in the course of their disease than nonsignaling mAbs (against MHC class II), despite delivering a lower total radiation dose.
52. 131I-labeled anti-CD20 mAb B1, using the non-myeloablative approach. This led to a 79% response rate (50% complete) and a median duration of response of 357 days, illustrating the success of this radiolabelled signaling mAb.
53. 131I-labelled anti-CD20 mAb B1 in a myeloablative regime with stem cell rescue. Major responses occurred in 86% of cases (79% complete remissions) with remissions lasting 27-87 months, demonstrating the potency of this approach and the durability of the remission.
54. Woolf EA, Schreiber GJ, Cosand WL, Raff HV Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res. 53:1993;2560-2565.
55. Ghetie M-A, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci USA. 94:1998;7509-7514.
56. Renschler MF, Wada HG, Fok KS, Levy R B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotype antibody to induce extracellular acidification. Cancer Res. 55:1995;5642-5647.
57. + T cells.